Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

New research into GLP-1 receptor has opened a realm of new treatment possibilities to treat opioid use disorder (OUD), a ...

PASADENA, CA, USA I February 25, 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent study.

The NHS medical director has cautioned about the side effects of certain medications following the latest findings ...

Recent research found that weight loss drugs like Ozempic may be contributing to a national trend of thyroid cancer ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...

GLP-1 receptor agonists are transforming obesity treatment, but manufacturing challenges must be addressed to meet rising ...

TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25New ...

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...

Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...